CellSource Co Ltd
TSE:4880
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 107
1 664
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
CellSource Co Ltd
CellSource Co Ltd
Cash & Cash Equivalents
CellSource Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CellSource Co Ltd
TSE:4880
|
Cash & Cash Equivalents
¥4.8B
|
CAGR 3-Years
40%
|
CAGR 5-Years
80%
|
CAGR 10-Years
N/A
|
|
|
CMIC Holdings Co Ltd
TSE:2309
|
Cash & Cash Equivalents
¥11.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
6%
|
|
|
C
|
Chiome Bioscience Inc
TSE:4583
|
Cash & Cash Equivalents
¥1.2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-7%
|
|
|
Precision System Science Co Ltd
TSE:7707
|
Cash & Cash Equivalents
¥1.9B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-5%
|
|
|
Medinet Co Ltd
TSE:2370
|
Cash & Cash Equivalents
¥4.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
35%
|
CAGR 10-Years
6%
|
|
|
WDB coco Co Ltd
TSE:7079
|
Cash & Cash Equivalents
¥2.7B
|
CAGR 3-Years
28%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
CellSource Co Ltd
Glance View
CellSource Co., Ltd. engages in regenerative medicine related business. The company is headquartered in Shibuya-Ku, Tokyo-To and currently employs 90 full-time employees. The company went IPO on 2019-10-28. The firm operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.
See Also
What is CellSource Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
4.8B
JPY
Based on the financial report for Oct 31, 2023, CellSource Co Ltd's Cash & Cash Equivalents amounts to 4.8B JPY.
What is CellSource Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
80%
Over the last year, the Cash & Cash Equivalents growth was 53%. The average annual Cash & Cash Equivalents growth rates for CellSource Co Ltd have been 40% over the past three years , 80% over the past five years .
You don't have any saved screeners yet
